Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;31(3):493-509.

CROI 2023: Acute and Post-Acute COVID-19

Annukka A R Antar  1 , Michael J Peluso  2
Affiliations

CROI 2023: Acute and Post-Acute COVID-19

Annukka A R Antar et al. Top Antivir Med. 2023 May.

Abstract

Studies of acute and post-acute COVID-19 were presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). Early treatment with ensitrelvir, a novel protease inhibitor, hastened viral clearance and symptom resolution during coronavirus disease 2019 (COVID-19) and appeared to reduce the prevalence of long COVID symptoms. The development of novel agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including those with broader sarbecovirus activity such as anti-angiotensin-converting enzyme 2 monoclonal antibodies, is underway. A growing understanding of the pathophysiology of long COVID has provided several potential therapeutic targets for individuals experiencing this condition. Efforts to understand COVID-19 in people with HIV have led to novel insights into the biology and natural history of SARS-CoV-2 coinfection in this vulnerable subpopulation. These and other studies are summarized herein.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–455. doi:10.1111/all.14657 - DOI - PubMed
    1. Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death-United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):459–465. doi:10.15585/mmwr.mm7112e1 - DOI - PMC - PubMed
    1. Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023 March 15. (Online ahead of print). doi:10.1016/S1473-3099(23)00118-4 - DOI - PMC - PubMed
    1. Wongvibulsin S, Garibaldi BT, Antar AAR, et al. Development of evere COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Intern Med. 2021;174(6):777–785. doi:10.7326/M20-6754 - DOI - PMC - PubMed
    1. Buttia C, Llanaj E, Raeisi-Dehkordi H, et al. Prognostic models in COVID-19 infection that predict severity: a systematic review. Eur J Epidemiol. 2023;1–18. doi:10.1007/s10654-023-00973-x - DOI - PMC - PubMed